Bydureon generic
Bydureon is an anti-diabetic drug owned by Astrazeneca Ab. It was first authorized for market use on January 27, 2012. The active ingredient in Bydureon is exenatide synthetic, and it is available in a suspension format for extended release subcutaneous use.
When will Bydureon generic be available?
The generic version of Bydureon may become available after July 18, 2030, which coincides with the expiry date of its last patent. This allows other manufacturers to produce a generic version of the drug.
Bydureon uses
Bydureon can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It works in combination with various other drugs such as dapagliflozin, metformin, insulin, a sulfonylurea, or a thiazolidinedione. This drug can also be used in patients as young as 10 years of age in combination with other treatments. By administering a sustained-release exenatide formulation, Bydureon can effectively improve glycemic control, reduce fasting plasma glucose, reduce body weight and reduce HbA1c in adults with type 2 diabetes mellitus.
Bydureon patent expiration
Bydureon is protected by 43 patents, with 3 already expired. The last patent for Bydureon is expected to expire on July 18, 2030, paving the way for the production of Bydureon generic. Below are the details of the patent: